Scott Blumberg Sells 808 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 808 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $19.79, for a total value of $15,990.32. Following the sale, the chief financial officer owned 118,334 shares of the company’s stock, valued at approximately $2,341,829.86. This represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Scott Blumberg also recently made the following trade(s):

• On Monday, December 22nd, Scott Blumberg sold 36,000 shares of CeriBell stock. The shares were sold at an average price of $21.00, for a total value of $756,000.00.

CeriBell Stock Up 2.3%

NASDAQ:CBLL opened at $19.39 on Friday. CeriBell, Inc. has a one year low of $10.01 and a one year high of $25.37. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.73 and a quick ratio of 12.25. The company has a market cap of $719.29 million, a PE ratio of -13.19 and a beta of 1.03. The firm’s 50 day simple moving average is $21.17 and its 200 day simple moving average is $16.21.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The company had revenue of $24.78 million for the quarter, compared to analyst estimates of $23.95 million. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. On average, research analysts anticipate that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

CBLL has been the topic of a number of analyst reports. JPMorgan Chase & Co. reduced their price objective on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. BTIG Research reiterated a “buy” rating and set a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. Canaccord Genuity Group boosted their price target on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, TD Cowen reissued a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, CeriBell has a consensus rating of “Moderate Buy” and a consensus target price of $24.67.

Key Headlines Impacting CeriBell

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Q4 results beat estimates — CeriBell reported Q4 EPS of ($0.36) vs. consensus ($0.43) and revenue of $24.78M vs. $23.95M expected, a fundamental beat that supports the share uptick. Zacks: Q4 Loss, Beats Revenue
• Positive Sentiment: Management set FY‑2026 revenue guidance (~$111M–$115M) roughly in line with consensus, giving investors a clearer growth target for the year. Business Insider: Full Year Results & Guidance
• Positive Sentiment: Earnings call emphasized accelerating revenue and market expansion — management commentary reinforced the beat/guidance story and helped push sentiment positive. Yahoo Finance: Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Short‑interest data for February appears unreliable (reported as zero/NaN) and provides no actionable signal at this time.
• Negative Sentiment: Clustered insider selling — several senior executives (CEO Xingjuan Chao, CFO Scott Blumberg, CTO Raymond Woo, CRO Joseph Manni and a VP) sold modest amounts at ~$19.8–$20.0, trimming positions by fractions of a percent; sales are small relative to total holdings but can create short‑term concern. InsiderTrades: Insider Sales

Hedge Funds Weigh In On CeriBell

Several hedge funds have recently made changes to their positions in CBLL. Invesco Ltd. lifted its holdings in CeriBell by 15.5% during the 4th quarter. Invesco Ltd. now owns 12,037 shares of the company’s stock worth $264,000 after purchasing an additional 1,618 shares in the last quarter. Creek Drive Management Group LLC bought a new stake in CeriBell in the 4th quarter worth approximately $4,253,000. nVerses Capital LLC purchased a new stake in CeriBell in the fourth quarter worth approximately $282,000. Tudor Investment Corp ET AL bought a new position in CeriBell during the fourth quarter valued at approximately $548,000. Finally, Engineers Gate Manager LP purchased a new position in shares of CeriBell during the fourth quarter worth approximately $260,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.